Pathophysiological Insights from a Case of Reversible Pulmonary Arterial Hypertension

Nakanishi T. , Sobue I. , Toyokura Y. . The Crow—Fukase syndrome; a study of 102 cases in Japan. Neurology 1984; 34: 712–20

Miralles G.D. , O'Fallon J.R. , Talley N.J. Plasma cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992; 327: 1919–23

Soubrier M. , Dubost J.J. , Sere A.F. . Growth factors in POEMS syndrome; evidence for marked increase in VEGF. Arthritis Rheum 1997; 40: 786–7

Hirose S. , Hosoda Y. , Furuya S. . Expression of VEGF and its receptors correlates closely with formation of plexiform lesion in human pulmonary hypertension. Pathol Int 2000; 50: 472–9

Sanchez O. , Humbert M. , Sitbon O. , Simonneaue G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273–7

Paciocco G. , Bossone E. , Erba H. . Reversible pulmonary hypertension in POEMS syndrome—another etiology of triggered vasculopathy? Can J Cardiol 2000; 16: 975–81

Gherardi R.M. , Belec L. , Soubrier D. . Overproduction of proinflammatory cytokines balanced by their antagonists in POEMS syndrome. Blood 1996; 87: 1458–65

Lesprit P. , Godeau B. , Francois-Jerome A. . Pulmonary hypertension in POEMS syndrome. A new feature mediated by cytokines. Am J Respir Crit Care Med 1998; 157: 907–11